190 related articles for article (PubMed ID: 24748476)
41. Doxorubicin triggers bioenergetic failure and p53 activation in mouse stem cell-derived cardiomyocytes.
Cunha-Oliveira T; Ferreira LL; Coelho AR; Deus CM; Oliveira PJ
Toxicol Appl Pharmacol; 2018 Jun; 348():1-13. PubMed ID: 29653124
[TBL] [Abstract][Full Text] [Related]
42. Protective Effects of a Novel Agonist of Galanin Receptors Against Doxorubicin-Induced Cardiotoxicity in Rats.
Studneva I; Palkeeva M; Veselova O; Molokoedov A; Ovchinnikov M; Sidorova M; Pisarenko O
Cardiovasc Toxicol; 2019 Apr; 19(2):136-146. PubMed ID: 30238355
[TBL] [Abstract][Full Text] [Related]
43. Protective effect of lncRNA CRNDE on myocardial cell apoptosis in heart failure by regulating HMGB1 cytoplasm translocation through PARP-1.
Chen H; Liu J; Wang B; Li Y
Arch Pharm Res; 2020 Dec; 43(12):1325-1334. PubMed ID: 33249529
[TBL] [Abstract][Full Text] [Related]
44. Basigin Promotes Cardiac Fibrosis and Failure in Response to Chronic Pressure Overload in Mice.
Suzuki K; Satoh K; Ikeda S; Sunamura S; Otsuki T; Satoh T; Kikuchi N; Omura J; Kurosawa R; Nogi M; Numano K; Sugimura K; Aoki T; Tatebe S; Miyata S; Mukherjee R; Spinale FG; Kadomatsu K; Shimokawa H
Arterioscler Thromb Vasc Biol; 2016 Apr; 36(4):636-46. PubMed ID: 26916734
[TBL] [Abstract][Full Text] [Related]
45. Mechanistic clues to the protective effect of chrysin against doxorubicin-induced cardiomyopathy: Plausible roles of p53, MAPK and AKT pathways.
Mantawy EM; Esmat A; El-Bakly WM; Salah ElDin RA; El-Demerdash E
Sci Rep; 2017 Jul; 7(1):4795. PubMed ID: 28684738
[TBL] [Abstract][Full Text] [Related]
46. Role of HMGB1 in doxorubicin-induced myocardial apoptosis and its regulation pathway.
Yao Y; Xu X; Zhang G; Zhang Y; Qian W; Rui T
Basic Res Cardiol; 2012 May; 107(3):267. PubMed ID: 22527657
[TBL] [Abstract][Full Text] [Related]
47. Mesenchymal Stem Cell-Derived Small Extracellular Vesicles Protect Cardiomyocytes from Doxorubicin-Induced Cardiomyopathy by Upregulating Survivin Expression via the miR-199a-3p-Akt-Sp1/p53 Signaling Pathway.
Lee JY; Chung J; Byun Y; Kim KH; An SH; Kwon K
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281156
[TBL] [Abstract][Full Text] [Related]
48. Advantages of prophylactic versus conventionally scheduled heart failure therapy in an experimental model of doxorubicin-induced cardiomyopathy.
Lódi M; Priksz D; Fülöp GÁ; Bódi B; Gyöngyösi A; Nagy L; Kovács Á; Kertész AB; Kocsis J; Édes I; Csanádi Z; Czuriga I; Kisvárday Z; Juhász B; Lekli I; Bai P; Tóth A; Papp Z; Czuriga D
J Transl Med; 2019 Jul; 17(1):229. PubMed ID: 31324258
[TBL] [Abstract][Full Text] [Related]
49. Enhanced-autophagy by exenatide mitigates doxorubicin-induced cardiotoxicity.
Lee KH; Cho H; Lee S; Woo JS; Cho BH; Kang JH; Jeong YM; Cheng XW; Kim W
Int J Cardiol; 2017 Apr; 232():40-47. PubMed ID: 28159361
[TBL] [Abstract][Full Text] [Related]
50. Inhibition of Fas-associated death domain-containing protein (FADD) protects against myocardial ischemia/reperfusion injury in a heart failure mouse model.
Fan Q; Huang ZM; Boucher M; Shang X; Zuo L; Brinks H; Lau WB; Zhang J; Chuprun JK; Gao E
PLoS One; 2013; 8(9):e73537. PubMed ID: 24058479
[TBL] [Abstract][Full Text] [Related]
51. Overexpression of A kinase interacting protein 1 attenuates myocardial ischaemia/reperfusion injury but does not influence heart failure development.
Booij HG; Yu H; De Boer RA; van de Kolk CW; van de Sluis B; Van Deursen JM; Van Gilst WH; Silljé HH; Westenbrink BD
Cardiovasc Res; 2016 Aug; 111(3):217-26. PubMed ID: 27302402
[TBL] [Abstract][Full Text] [Related]
52. HSP27 regulates p53 transcriptional activity in doxorubicin-treated fibroblasts and cardiac H9c2 cells: p21 upregulation and G2/M phase cell cycle arrest.
Venkatakrishnan CD; Dunsmore K; Wong H; Roy S; Sen CK; Wani A; Zweier JL; Ilangovan G
Am J Physiol Heart Circ Physiol; 2008 Apr; 294(4):H1736-44. PubMed ID: 18263706
[TBL] [Abstract][Full Text] [Related]
53. LongShengZhi capsule inhibits doxorubicin-induced heart failure by anti-oxidative stress.
Xu S; Wang Y; Yu M; Wang D; Liang Y; Chen Y; Liao C; Xie Z; Zhao B; Han J; Duan Y; Yang X
Biomed Pharmacother; 2020 Mar; 123():109803. PubMed ID: 31877550
[TBL] [Abstract][Full Text] [Related]
54. Wnt signaling is critical for maladaptive cardiac hypertrophy and accelerates myocardial remodeling.
Malekar P; Hagenmueller M; Anyanwu A; Buss S; Streit MR; Weiss CS; Wolf D; Riffel J; Bauer A; Katus HA; Hardt SE
Hypertension; 2010 Apr; 55(4):939-45. PubMed ID: 20177000
[TBL] [Abstract][Full Text] [Related]
55. Intercellular Adhesion Molecule 1 Regulates Left Ventricular Leukocyte Infiltration, Cardiac Remodeling, and Function in Pressure Overload-Induced Heart Failure.
Salvador AM; Nevers T; Velázquez F; Aronovitz M; Wang B; Abadía Molina A; Jaffe IZ; Karas RH; Blanton RM; Alcaide P
J Am Heart Assoc; 2016 Mar; 5(3):e003126. PubMed ID: 27068635
[TBL] [Abstract][Full Text] [Related]
56. Overexpression of Heat Shock Protein 70 Improves Cardiac Remodeling and Survival in Protein Phosphatase 2A-Expressing Transgenic Mice with Chronic Heart Failure.
Yoon S; Gergs U; McMullen JR; Eom GH
Cells; 2021 Nov; 10(11):. PubMed ID: 34831402
[TBL] [Abstract][Full Text] [Related]
57. Xinshuitong Capsule extract attenuates doxorubicin-induced myocardial edema via regulation of cardiac aquaporins in the chronic heart failure rats.
Tan C; Zeng J; Wu G; Zheng L; Huang M; Huang X
Biomed Pharmacother; 2021 Dec; 144():112261. PubMed ID: 34628163
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of pulsed Doppler tissue velocity imaging for assessing systolic function of murine global heart failure.
Matoba S; Hwang PM; Nguyen T; Shizukuda Y
J Am Soc Echocardiogr; 2005 Feb; 18(2):148-54. PubMed ID: 15682052
[TBL] [Abstract][Full Text] [Related]
59. Parthenolide reverses doxorubicin resistance in human lung carcinoma A549 cells by attenuating NF-κB activation and HSP70 up-regulation.
Xin Y; Yin F; Qi S; Shen L; Xu Y; Luo L; Lan L; Yin Z
Toxicol Lett; 2013 Aug; 221(2):73-82. PubMed ID: 23792430
[TBL] [Abstract][Full Text] [Related]
60. Influence of p53 in the transition of myotrophin-induced cardiac hypertrophy to heart failure.
Das B; Young D; Vasanji A; Gupta S; Sarkar S; Sen S
Cardiovasc Res; 2010 Aug; 87(3):524-34. PubMed ID: 20202977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
